{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:36:12Z","timestamp":1788042972298,"version":"build-2784847793"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jocn.2021.05.028","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:22:28Z","timestamp":1621556548000},"page":"279-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Utility of monitoring the serum levetiracetam concentration for intraoperative seizure control during awake craniotomy"],"prefix":"10.1016","volume":"89","author":[{"given":"Ryohei","family":"Otani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyu","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kushihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobusada","family":"Shinoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2021.05.028_b0005","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1016\/j.wneu.2018.08.243","article-title":"Awake craniotomy for resection of brain metastases: a systematic review","volume":"120","author":"Chua","year":"2018","journal-title":"World Neurosurg"},{"issue":"3","key":"10.1016\/j.jocn.2021.05.028_b0010","doi-asserted-by":"crossref","DOI":"10.23736\/S0390-5616.16.03880-7","article-title":"Intraoperative seizures and seizures outcome in patients undergoing awake craniotomy","volume":"63","author":"Yuan","year":"2019","journal-title":"J Neurosurg Sci"},{"issue":"3","key":"10.1016\/j.jocn.2021.05.028_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2176\/nmc.52.119","article-title":"Guidelines committee of the Japan awake surgery c. The guidelines for awake craniotomy guidelines committee of the Japan awake surgery conference","volume":"52","author":"Kayama","year":"2012","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.jocn.2021.05.028_b0020","article-title":"A systemic review of levetiracetam versus phenytoin in the prevention of late post-traumatic seizures and survey of UK neurosurgical prescribing practice of antiepileptic medication in acute traumatic brain injury","volume":"1\u20137","author":"Bakr","year":"2018","journal-title":"Br J Neurosurg"},{"issue":"6","key":"10.1016\/j.jocn.2021.05.028_b0025","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jocn.2014.12.013","article-title":"Levetiracetam versus phenytoin in management of status epilepticus","volume":"22","author":"Chakravarthi","year":"2015","journal-title":"J Clin Neurosci"},{"issue":"2","key":"10.1016\/j.jocn.2021.05.028_b0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12028-013-9951-x","article-title":"Levetiracetam versus phenytoin: a comparison of efficacy of seizure prophylaxis and adverse event risk following acute or subacute subdural hematoma diagnosis","volume":"21","author":"Radic","year":"2014","journal-title":"Neurocrit Care"},{"issue":"6","key":"10.1016\/j.jocn.2021.05.028_b0035","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/ane.12928","article-title":"Why we prefer levetiracetam over phenytoin for treatment of status epilepticus","volume":"137","author":"Zaccara","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.jocn.2021.05.028_b0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40268-016-0148-6","article-title":"An updated overview on therapeutic drug monitoring of recent antiepileptic drugs","volume":"16","author":"Jacob","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.jocn.2021.05.028_b0045","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303-11; discussion 12-3."},{"issue":"6","key":"10.1016\/j.jocn.2021.05.028_b0050","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.jocn.2021.05.028_b0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jocn.2021.05.028_b0060","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.18433\/jpps30081","article-title":"Therapeutic drug monitoring of levetiracetam in select populations","volume":"21","author":"Jarvie","year":"2018","journal-title":"J Pharm Pharm Sci"},{"issue":"8","key":"10.1016\/j.jocn.2021.05.028_b0065","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.braindev.2014.11.008","article-title":"The efficacy of levetiracetam for focal seizures and its blood levels in children","volume":"37","author":"Iwasaki","year":"2015","journal-title":"Brain Dev"},{"issue":"8","key":"10.1016\/j.jocn.2021.05.028_b0070","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clineuro.2011.05.007","article-title":"Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage","volume":"113","author":"Mink","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"10.1016\/j.jocn.2021.05.028_b0075","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/0883073809348795","article-title":"Intravenous levetiracetam in children with seizures: a prospective safety study","volume":"25","author":"Ng","year":"2010","journal-title":"J Child Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2021.05.028_b0080","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007691-200312000-00007","article-title":"Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication","volume":"25","author":"May","year":"2003","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821002460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821002460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:28:26Z","timestamp":1760822906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821002460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":16,"alternative-id":["S0967586821002460"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.05.028","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of monitoring the serum levetiracetam concentration for intraoperative seizure control during awake craniotomy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}